White Pine Capital LLC acquired a new stake in Amgen Inc. (NASDAQ:AMGN – Free Report) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,114 shares of the medical research company’s stock, valued at approximately $470,000.
Several other large investors have also bought and sold shares of the stock. Rational Advisors Inc. lifted its holdings in Amgen by 13.7% during the 2nd quarter. Rational Advisors Inc. now owns 199 shares of the medical research company’s stock worth $72,000 after buying an additional 24 shares during the period. Beacon Financial Advisory LLC raised its position in shares of Amgen by 2.0% during the second quarter. Beacon Financial Advisory LLC now owns 1,274 shares of the medical research company’s stock worth $461,000 after acquiring an additional 25 shares during the last quarter. James T. Borello RIA lifted its stake in shares of Amgen by 13.6% in the third quarter. James T. Borello RIA now owns 209 shares of the medical research company’s stock worth $88,000 after acquiring an additional 25 shares during the period. Sweeney & Michel LLC lifted its stake in shares of Amgen by 0.5% in the third quarter. Sweeney & Michel LLC now owns 5,129 shares of the medical research company’s stock worth $2,162,000 after acquiring an additional 25 shares during the period. Finally, Legacy Financial Advisors Inc. lifted its stake in shares of Amgen by 0.8% in the second quarter. Legacy Financial Advisors Inc. now owns 3,407 shares of the medical research company’s stock worth $1,234,000 after acquiring an additional 26 shares during the period. 76.50% of the stock is owned by institutional investors.
Amgen Stock Performance
AMGN stock opened at $462.32 on Tuesday. The stock has a 50-day moving average price of $425.81 and a 200-day moving average price of $381.77. Amgen Inc. has a 1-year low of $312.39 and a 1-year high of $483.99. The company has a current ratio of 1.48, a quick ratio of 1.20 and a debt-to-equity ratio of 3.60. The firm has a market cap of $250.07 billion, a PE ratio of 26.82, a price-to-earnings-growth ratio of 3.25 and a beta of 0.43.
Amgen (NASDAQ:AMGN – Get Free Report) last announced its quarterly earnings data on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.79 by $0.66. Amgen had a return on equity of 114.99% and a net margin of 24.14%. The company had revenue of $10.37 billion for the quarter, compared to the consensus estimate of $10.07 billion. During the same period in the previous year, the business earned $5.64 EPS. The firm’s revenue was up 8.5% compared to the same quarter last year. As a group, equities research analysts expect that Amgen Inc. will post 23.37 earnings per share for the current year.
Amgen Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Friday, December 11th. Shareholders of record on Friday, November 20th will be issued a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date is Friday, November 20th. Amgen’s payout ratio is presently 58.47%.
Wall Street Analyst Weigh In
Several analysts recently commented on the company. Jefferies Financial Group reiterated a “hold” rating and issued a $410.00 target price on shares of Amgen in a report on Wednesday, September 23rd. Truist Financial raised their price target on shares of Amgen from $380.00 to $398.00 and gave the stock a “hold” rating in a report on Wednesday, November 4th. UBS Group boosted their price target on shares of Amgen from $470.00 to $530.00 and gave the stock a “buy” rating in a research report on Wednesday, November 4th. Canaccord Genuity Group boosted their price target on shares of Amgen from $384.00 to $440.00 and gave the stock a “hold” rating in a research report on Wednesday, November 4th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Amgen from $350.00 to $425.00 and gave the company a “neutral” rating in a research note on Wednesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, eighteen have assigned a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, Amgen presently has an average rating of “Hold” and a consensus price target of $425.69.
Get Our Latest Stock Analysis on AMGN
Amgen Profile
Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.
Read More
- Five stocks we like better than Amgen
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.
